Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Garufi G, Carbognin L, Arcanà C, Parola S, Ventriglia A, Doronzo A, Garutti M, Orlandi A, Palazzo A, Fabi A, Bria E, Tortora G, Arpino G, Giuliano M, Del Mastro L, De Laurentiis M, Puglisi F. Garufi G, et al. Among authors: bria e. Cancer Treat Rev. 2022 Nov;110:102454. doi: 10.1016/j.ctrv.2022.102454. Epub 2022 Aug 11. Cancer Treat Rev. 2022. PMID: 35987149 Review.
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papaldo P, Fabi A, Nisticò C, Di Cosimo S, Ruggeri EM, Milella M, Mottolese M, Terzoli E, Cognetti F. Carlini P, et al. Among authors: bria e. Cancer. 2005 Oct 1;104(7):1335-42. doi: 10.1002/cncr.21339. Cancer. 2005. PMID: 16088965 Free article. Review.
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Carlini P, Michelotti A, Ferretti G, Ricci S, Giannarelli D, Pellegrini M, Cresti N, Di Cosimo S, Bria E, Papaldo P, Fabi A, Ruggeri EM, Milella M, Alimonti A, Salesi N, Cognetti F. Carlini P, et al. Among authors: bria e. Cancer Invest. 2007 Mar;25(2):102-5. doi: 10.1080/07357900701224789. Cancer Invest. 2007. PMID: 17453821
Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nisticò C, Cuppone F, Metro G, Terzoli E, Cognetti F, Ferretti G. Carlini P, et al. Among authors: bria e. Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36. doi: 10.1517/13543784.16.7.1023. Expert Opin Investig Drugs. 2007. PMID: 17594187 Review.
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.
Fabi A, Ciccarese M, Metro G, Savarese A, Giannarelli D, Nuzzo CM, Russillo M, Sperduti I, Carbone I, Bria E, Cognetti F. Fabi A, et al. Among authors: bria e. Support Care Cancer. 2008 Dec;16(12):1375-80. doi: 10.1007/s00520-008-0438-9. Epub 2008 May 14. Support Care Cancer. 2008. PMID: 18478278 Clinical Trial.
383 results